Landing
Macula Society 2025
24-Month Results from the GALE Open-Label Extension Study: 48 Months of Continuous Pegcetacoplan
Retinal Sensitivity After 36 Months of Pegcetacoplan Treatment for Geographic Atrophy in the GALE Study
Fellow Eye Analysis in Bilateral GA due to AMD: Long-term Data from the OAKS, DERBY, and GALE Studies
Development and Validation of a Time-to-event Risk Calculator for Patients with Geographic Atrophy (GA) Secondary to AMD
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.